Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Neuronetics Inc (NQ: STIM )

3.555 +0.185 (+5.49%)
Official Closing Price Updated: 4:15 PM EDT, May 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 52,340
Open 3.380
Bid (Size) 3.550 (3)
Ask (Size) 3.560 (9)
Prev. Close 3.370
Today's Range 3.380 - 3.690
52wk Range 1.030 - 5.070
Shares Outstanding 29,756,053
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
NeuroStar® TMS Advances Treatment for Adolescents During Mental Health Awareness Month
The Company is highlighting stories from adolescents with major depressive disorder on the heels of groundbreaking FDA clearance 
From Neuronetics
Via GlobeNewswire
New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is Vital
Lack of early symptom improvement is not predictive of final responder status 
From Neuronetics
Via GlobeNewswire

Performance

YTD
+29.27%
+29.27%
1 Month
-26.09%
-26.09%
3 Month
+4.56%
+4.56%
6 Month
+209.13%
+209.13%
1 Year
+58.00%
+58.00%

More News

Read More
Top 5 Health Care Stocks That May Plunge In March
Via Benzinga
Earnings Outlook For Neuronetics
Via Benzinga
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
NeuroStar® Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with Depression
From Neuronetics
Via GlobeNewswire
Neuronetics Announces 5-Year Exclusive Partnership with Transformations Care Network
From Neuronetics
Via GlobeNewswire
Earnings Scheduled For March 5, 2024
Via Benzinga
Neuronetics Launches Latest Evolution in its TrakStar® Patient Data Management System
From Neuronetics
Via GlobeNewswire
NeuroStar TMS Patient Access Expands Through Lucet Health Policy Update
From Neuronetics
Via GlobeNewswire
Neuronetics Receives 510(k) Clearance for NeuroSite™ Coil Placement Accessory
From Neuronetics
Via GlobeNewswire
NeuroStar TMS Receives Expanded Regulatory Approval in Japan
From Neuronetics
Via GlobeNewswire
NeuroStar Elevates Depression Treatment with Cutting-Edge Technology Advancements
From Neuronetics
Via GlobeNewswire
Neuronetics Announces Continued Momentum from Health Plans for TMS Therapy Coverage
From Neuronetics
Via GlobeNewswire
Brain Stimulation Highlights Best Practices for Optimal TMS Treatment Outcomes
From Neuronetics
Via GlobeNewswire
Earnings Scheduled For November 7, 2023
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
In Recognition of Suicide Prevention Month, NeuroStar Voices Portal Amplifies Stories of Real People Beating Depression
From Neuronetics
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
NeuroStar Advanced Therapy Wins 2023 dotCOMM Awards
From Neuronetics
Via GlobeNewswire
Neuronetics Revolutionizes Patient Communication and Provider Support Through Its Exclusive TrakStar® Platform
From Neuronetics
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.